Safety and Efficacy of OBX-115 in Advanced Solid Tumors
A phase 1/2 trial of OBX-115 in melanoma and non-small-cell lung cancer, run by Obsidian Therapeutics, Inc., now recruiting.
Overview
Safety and Efficacy of OBX-115 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06060613 by Obsidian Therapeutics, Inc., with 208 participants planned, started 2023-10-25 and due to reach its primary completion in 2029-06-30. Interventions recorded: OBX-115.
Similar pages
not linked directly; found by shared links- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of GV20-0251 in Participants With Solid Tumor Malignancies
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TreatmentBA3071
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.